| Update on the mechanisms of liver regeneration ME Preziosi, SP Monga Seminars in liver disease 37 (02), 141-151, 2017 | 84 | 2017 |
| Deletion of the serotonin transporter in rats disturbs serotonin homeostasis without impairing liver regeneration RB Matondo, C Punt, J Homberg, MJM Toussaint, R Kisjes, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 296 (4 …, 2009 | 63 | 2009 |
| Metabolite profiling of the antisense oligonucleotide eluforsen using liquid chromatography-mass spectrometry J Kim, B Basiri, C Hassan, C Punt, E van der Hage, C den Besten, ... Molecular Therapy-Nucleic Acids 17, 714-725, 2019 | 47 | 2019 |
| Animal models for cystic fibrosis: a systematic search and mapping review of the literature–Part 1: genetic models CHC Leenaars, RBM De Vries, A Heming, D Visser, D Holthaus, ... Laboratory animals 54 (4), 330-340, 2020 | 19 | 2020 |
| Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset JK Paul J Wichgers Schreur, Petra Mooij , Gerrit Koopman , Babs E Verstrepen ... NPJ Vaccines 54 (7(1)), 2022 | 14 | 2022 |
| Animal models for cystic fibrosis: a systematic search and mapping review of the literature. Part 2: nongenetic models CHC Leenaars, RBM Vries, J Reijmer, D Holthaus, D Visser, A Heming, ... Laboratory Animals 55 (4), 307-316, 2021 | 3 | 2021 |
| Sustained release olanzapine formulations MA Smith, C Claassen-Punt US Patent App. 15/982,449, 2018 | 2 | 2018 |
| Sustained release olanzapine formulations MA Smith, C Claassen-Punt US Patent App. 15/271,508, 2017 | 2 | 2017 |
| Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 … I Leroux-Roels, CK Prajeeth, A Aregay, N Nair, GF Rimmelzwaan, ... The Lancet Infectious Diseases 24 (11), 1245-1253, 2024 | 1 | 2024 |
| Sustained release olanzapine formulations C Claassen-Punt, MA Smith, L Chen, AA Gershon US Patent 10,646,443, 2020 | 1 | 2020 |
| Sustained release olanzapine formulations MA Smith, C Claassen-Punt US Patent App. 18/623,327, 2024 | | 2024 |
| Safety and immunogenicity of the live-attenuated candidate vaccine ‘hRVFV-4s’ against Rift Valley fever in healthy adults PJW Schreur, C Punt, I Leroux-Roels Paradigm Shifts for Global One Health, 116-116, 2024 | | 2024 |
| Formulaciones de olanzapina de liberación sostenida M Smith, C Claassen-Punt ES Patent App. 16,775,424 T, 2024 | | 2024 |
| Formulacje olanzapiny o przedłużonym uwalnianiu MA Smith, C CLAASSEN-PUNT | | 2024 |
| Sustained release olanzapine formulations C Claassen-Punt, MA Smith, L Chen, AA Gershon US Patent 11,813,359, 2023 | | 2023 |
| Olanzapinformuleringer med langvarig frigivelse MA Smith, C Claassen-Punt | | 2023 |
| Pitkitetysti vapauttavia olantsapiiniformulaatioita M Smith, C Claassen-Punt | | 2023 |
| Sustained release olanzapine formulations MA Smith, C Claassen-Punt US Patent App. 17/847,685, 2022 | | 2022 |
| Olanzapine sustained release pharmaceutical preparation MA Smith, C Claassen-Punt | | 2022 |
| Sustained release olanzapine formulations MA Smith, C Claassen-Punt | | 2018 |
